Abstract
Liver cirrhosis favors portal hypertension which causes complications like variceal bleeding, therapy-refractory ascites, and hepatorenal syndrome. Transjugular intrahepatic portosystemic shunt (TIPS) is used for the treatment of portal hypertension. However, parenchymal portal venous flow after TIPS insertion is reduced. TIPS therefore might induce ischemic liver injury which has been discussed to favor hepatocarcinogenesis resulting in the development of hepatocellular cancer (HCC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
